Supplementary Data Tables 1 from Immunogenomic Landscape of Neuroendocrine Prostate Cancer

Supplementary Data Tables 1 from Immunogenomic Landscape of Neuroendocrine Prostate Cancer

<p>Suppl Table S1. Clinical characteristics of metastatic patient cohortSuppl Table S2. The 361 gene signature identified in this study to classify T-cell immune clustersSuppl Table S3. The 80 immune and stroma related gene signatures used to quantify the TMESuppl Table S4. DEGs for SCLC versu...

Descripció completa

Guardat en:

Dades bibliogràfiques
Autor principal:	Bhavneet Bhinder (14963342) (author)
Altres autors:	Alison Ferguson (16424081) (author), Michael Sigouros (15045498) (author), Manik Uppal (14963345) (author), Ahmed G. Elsaeed (16424084) (author), Rohan Bareja (16424087) (author), Hussein Alnajar (16424090) (author), Kenneth Wha Eng (15382259) (author), Vincenza Conteduca (15045492) (author), Andrea Sboner (14963351) (author), Juan Miguel Mosquera (16424093) (author), Olivier Elemento (14956746) (author), Himisha Beltran (15284954) (author)
Publicat:	2025
Matèries:	Cancer Tumor Biology Clinical Research and Trials Genitourinary Cancers Prostate cancer Precision Medicine Tumor Microenvironment Immune cells and the microenvironment
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars

Supplementary Figure S1 from Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
per: Zachary Quinn (15052893)
Publicat: (2025)

Supplementary Table S2 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
per: Holly Tovey (16824233)
Publicat: (2025)

Supplementary Table S3 from Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)
per: Holly Tovey (16824233)
Publicat: (2025)

Supplementary Tables S1-S4 from Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial
per: Axel Stenmark Tullberg (15029928)
Publicat: (2025)

Figure 1 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
per: Robert L. Hollis (15034814)
Publicat: (2025)

Figure 2 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
per: Robert L. Hollis (15034814)
Publicat: (2025)

Figure 3 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
per: Robert L. Hollis (15034814)
Publicat: (2025)

Figure 4 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
per: Robert L. Hollis (15034814)
Publicat: (2025)

Figure 5 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
per: Robert L. Hollis (15034814)
Publicat: (2025)

Table 1 from Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
per: Robert L. Hollis (15034814)
Publicat: (2025)

Supplementary Data 1 from Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
per: Alexander N. Shoushtari (15023909)
Publicat: (2025)

Suppl Data 2 from Whole Slide Imaging-Based Prediction of <i>TP53</i> Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer
per: Marija Pizurica (17060224)
Publicat: (2025)

Suppl. Data 1 from Whole Slide Imaging-Based Prediction of <i>TP53</i> Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer
per: Marija Pizurica (17060224)
Publicat: (2025)

Supplementary Figure S1 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
per: James S. Wilmott (15008931)
Publicat: (2025)

Supplementary Tables S1-7 from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases
per: James S. Wilmott (15008931)
Publicat: (2025)

Figure 1 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
per: Natalie C. Fisher (15046025)
Publicat: (2025)

Figure 2 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
per: Natalie C. Fisher (15046025)
Publicat: (2025)

Figure 3 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
per: Natalie C. Fisher (15046025)
Publicat: (2025)

Figure 4 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
per: Natalie C. Fisher (15046025)
Publicat: (2025)

Figure 5 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
per: Natalie C. Fisher (15046025)
Publicat: (2025)

Figure 6 from Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
per: Natalie C. Fisher (15046025)
Publicat: (2025)

Figure 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
per: Clare Vesely (505402)
Publicat: (2025)

Figure 2 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
per: Clare Vesely (505402)
Publicat: (2025)

Figure 3 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
per: Clare Vesely (505402)
Publicat: (2025)

Figure 4 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
per: Clare Vesely (505402)
Publicat: (2025)

Figure 5 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
per: Clare Vesely (505402)
Publicat: (2025)

Table 1 from Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
per: Clare Vesely (505402)
Publicat: (2025)

Supplementary Data from DNA Methylation Landscapes of Prostate Cancer Brain Metastasis Are Shaped by Early Driver Genetic Alterations
per: John Gallon (15096459)
Publicat: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
per: Ulka N. Vaishampayan (15051039)
Publicat: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
per: Ulka N. Vaishampayan (15051039)
Publicat: (2025)

Supplementary Figure S3 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
per: Ulka N. Vaishampayan (15051039)
Publicat: (2025)

Supplementary Table S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
per: Ulka N. Vaishampayan (15051039)
Publicat: (2025)

Supplementary Data 1. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
per: Arian Lundberg (14960817)
Publicat: (2025)

Supplementary Data 2. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
per: Arian Lundberg (14960817)
Publicat: (2025)

Supplementary Figures 1 from Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors
per: Luana Guimaraes Sousa (16534377)
Publicat: (2025)

Table S2 from Hydrogen Sulfide Creates a Favorable Immune Microenvironment for Colon Cancer
per: Taohua Yue (14963045)
Publicat: (2025)

Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer
per: Kankan Cao (16437263)
Publicat: (2025)

Table S2 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression
per: Junfeng Xu (16437141)
Publicat: (2025)

Table S3 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression
per: Junfeng Xu (16437141)
Publicat: (2025)

Supplementary Table 1. from The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer
per: Arian Lundberg (14960817)
Publicat: (2025)

Cannot write session to /tmp/vufind_sessions/sess_ok2vsd3ras1pq7qnj6nd75s626